Medicenna Reports Updated Data From ABILITY-1 Trial

MT NewswiresDec 5, 2024 08:48 ET

Updated MDNA11 Monotherapy and Combination Clinical Data From the Ongoing Phase 1/2 ABILITY-1 Study to Be Presented at the 2024 Immunotherapy Bridge Conference

GlobeNewswireNov 27, 2024 07:00 ET

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at SNO Meeting

MT NewswiresNov 25, 2024 07:53 ET

Medicenna Q3 Loss Widens

MT NewswiresNov 15, 2024 08:16 ET

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

GlobeNewswireNov 13, 2024 07:00 ET

Medicenna Says ABILITY-1 Study Shows MDNA 11 Continues to Show Favourable Safety Profile

MT NewswiresNov 11, 2024 07:42 ET